Summit Reports 25% Lower Death Risk in Biliary Tract Cancer Trial

Median overall survival was 14.9 months with ivonescimab and chemotherapy, versus 12.1 months with durvalumab and chemotherapy in the late-stage trial conducted in China.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.